Drug Profile
EP 100
Alternative Names: EP-100Latest Information Update: 28 Mar 2024
Price :
$50
*
At a glance
- Originator Esperance Pharmaceuticals
- Class Antineoplastics; Peptides
- Mechanism of Action Cell membrane permeability enhancers; Cell membrane structure modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Ovarian cancer
- No development reported Cancer; Solid tumours
Most Recent Events
- 28 Mar 2024 No recent reports of development identified for preclinical development in Cancer in USA (IV)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Solid-tumours in USA (IV, Infusion)
- 05 Feb 2020 Phase-I development is still ongoing USA (Esperance Pharmaceuticals pipeline)